Trade AstraZeneca ^AZN

AstraZeneca Projects $80 Bln In Total Revenue By 2030, Sustained Growth Beyond

Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027

Ctrl, Alt, Cure: AI codes next miracle drug

AstraZeneca Highlights Breakthrough Cancer Data at ESMO 2026 Investor Update

Is AstraZeneca's Pipeline Fuel Enough to Spark a Post-Earnings Breakout on Oct. 30?

AstraZeneca's Sone-Ve Cuts Death Risk By 42% In Advanced Gastric Cancer Trial; Stock Up

AstraZeneca's Tagrisso Combo Achieves Significant Survival Benefit In Lung Cancer Trial; Stock Up

Cancer Innovation Must Not Become Corporate Spoils -By Fransiscus Nanga Roka

Dow Jones Top Company Headlines at 3 AM ET: Roche Targets Emerging Oncology Market With New Lung-Cancer Drug | AstraZeneca ... | Morningstar

UK Stock Market Today: FTSE 100 Futures Dip As Firm PMIs Meet Rate Worries

AstraZeneca's Sone-ve Drug Shows Promising Survival Rates in Advanced Stomach Cancer Trials, ETPharma

EMEA Morning Briefing: Central Bank Decisions in Focus This Week | Morningstar

Dow Jones Top Company Headlines at 1 AM ET: AstraZeneca Readies New Portfolio of Targeted Cancer Therapies | Musk ... | Morningstar

Dow Jones Top Company Headlines at 11 PM ET: AstraZeneca Readies New Portfolio of Targeted Cancer Therapies | Musk ... | Morningstar

Notorious Vancouver escort charged with robbery in Ontario | Watch News Videos Online

Amgen announces Phase 3 results of Imdelltra with AstraZeneca's Imfinzi

AstraZeneca announces results from the SAFFRON Phase III trial of Tagrisso

AstraZeneca announces results from DeLLphi-305 trial of IMFINZI

AstraZeneca announces results from VOLGA Phase III trial of IMFINZI

DZ BANK AG Reaffirms Their Buy Rating on arGEN X (0QW0)

New Amgen drug combination shows survival gains in lung cancer trial

Amgen-AstraZeneca drug combination cut risk of death in small cell lung cancer by 58%

Amgen Reports Combo Cuts Lung Cancer Death Risk 58%

8,009 Shares of Astrazeneca Plc $AZN Purchased by Sowell Financial Services LLC

Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial

Head-To-Head Contrast: Lifecore Biomedical (NASDAQ:LFCR) vs. Astrazeneca (NYSE:AZN) - Markets Daily

Contrasting Astrazeneca (NYSE:AZN) and Lifecore Biomedical (NASDAQ:LFCR) - Zolmax

Cancer Patents Must Protect Discovery Without Capturing Competition -By Fransiscus Nanga Roka

UK Stock Market Today: FTSE 100 Futures Edge Up On Sticky Inflation Test

Astrazeneca (AZN) Expected to Announce Quarterly Earnings on Friday

Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial

Astrazeneca Pharma India Ltd Stock Price: Astrazeneca Phar Share Price Today | India Infoline

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial

China-made cancer drug to go on sale in US after Americans travel to buy it

Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026

AstraZeneca's Ultomiris Gets FDA Accelerated Approval As First C5 Inhibitor For IgAN

AstraZeneca Adds New Indication for Ultomiris Drug in Rare Kidney Disease | Morningstar

AstraZeneca says Ultomiris approved to reduce proteinuria

Small Cell Lung Cancer Pipeline Analysis 2026: Phase III and Phase II Assets, MOA Breakdown, and Route of Administration Trends | AbbVie, Xcovery, Sanofi, Pfizer, Mirati Therapeutics, AstraZeneca | ABNewswire

Ovarian Cancer Pipeline 2026: Emerging Drugs, Regulatory Milestones, and Strategic Moves by Leading Players | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui, Boehringer Ingelheim, Impact | ABNewswire

Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: results from the randomized RuxoBEAT trial

Amgen (AMGN) Sales Grew 10%, but Can Earnings Catch Up to the Price?

Is AstraZeneca (AZN) Stock Cheap?

AbbVie vs. AstraZeneca: Which Pharma Giant Has the Stronger Earnings Growth Story?

Global Life Science Market Report 2026: Size, Trends and Forecast to 2030 | Secure $200.6B AI and Precision Medicine Upside with Johnson & Johnson, Roche, Pfizer, and AstraZeneca

3,292 Astrazeneca Plc $AZN Shares Sold by Quadrant Capital Group LLC - Daily Political

Clean Heat Program: Sanofi, UCB, and Opella join AstraZeneca

AstraZeneca and Oracle Join Forces to Revolutionize Clinical Trials with AI Technology, ETPharma

AstraZeneca and Amgen's Tezspire Achieves 69% Remission in Eosinophilic Esophagitis Trial, ETPharma

AI in Patient Recruitment: Revolutionizing Clinical Trial Enrollment for Faster, More Efficient Research

Oracle Corporation (ORCL) Stock: Rises as AstraZeneca AI Partnership Targets Clinical Trials

AstraZeneca Stocks Rise 2.7% as Tezspire Data Sharpen Expansion Case

Tech News Today, October 20, 2026: Amazon, Apple, ByteDance, Microsoft, Nvidia, OpenAI, Salesforce & More

Bank Pictet & Cie Europe AG Purchases 250,755 Shares of Astrazeneca Plc $AZN

AstraZeneca (AZN) Adds Oncology Catalysts. Is the Pipeline Worth Its Earnings Multiple?

Oracle (ORCL) Expands Its AI Healthcare Push With A New Drugmaker Partnership

AstraZeneca & Amgen's Tezspire Meets Phase 3 Endpoints In Eosinophilic Esophagitis

AstraZeneca's Tezspire Shows Sustained Benefits In Phase 3 Esophagitis Trial

AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial

AstraZeneca Pharma set to move its registered office to Maharashtra, from Karnataka

TEZSPIRE® DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITIS

AstraZeneca and Oracle team up on AI to find patients for drug trials

AstraZeneca (LON:AZN) Earns Buy Rating from Jefferies Financial Group

AstraZeneca partners with Oracle for AI-driven clinical trials

AstraZeneca Partners With Oracle to Refine Clinical Research With AI | Morningstar

AstraZeneca, Oracle launch first global AI program in Abu Dhabi: CEO

Oracle and AstraZeneca Partner to Advance AI-enabled Healthcare Innovation

10,000 Astrazeneca Plc $AZN Shares Acquired by Value Partners Investments Inc.

Astrazeneca Plc $AZN Shares Acquired by Abel Hall LLC - Markets Daily

Fadnavis Inaugurates AstraZeneca's New Mumbai Office

Jackson Square Capital LLC Buys New Stake in Astrazeneca Plc $AZN - Zolmax

Jackson Square Capital LLC Buys New Shares in Astrazeneca Plc $AZN

Rare prostate cancer histologies: detection, characteristics and treatment

Investors Buy Large Volume of Call Options on Astrazeneca (NYSE:AZN)

7,640 Shares in Astrazeneca Plc $AZN Acquired by New England Research & Management Inc.

439,578 Shares in Astrazeneca Plc $AZN Acquired by Vontobel Holding Ltd.

New England Research & Management Inc. Buys New Holdings in Astrazeneca Plc $AZN - Daily Political

Goelzer Investment Management Inc. Acquires 39,625 Shares of Astrazeneca Plc $AZN

Summit Therapeutics (SMMT) Stock Fair Value Edges Higher After AstraZeneca Deal And Trial Focus

Liver-specific amino acid metabolism impacts on efficacy of cancer immunotherapy

Clinics: Arrowhead's RNAi Aro-Mapt reduces tau in Alzheimer's by 73%

AstraZeneca's Shares Have Fallen, but Is 14.6x Forward Earnings a Buying Opportunity?

Weekly Buzz: RHHBY, TEVA Win FDA Nod; MLAB, GSK Cut Jobs; AZN, VIR Deals; KRYS, ABBV Report Data

Astrazeneca (NYSE:AZN) Stock Price Up 3.5% Following Analyst Upgrade - Markets Daily

Promising Manufacturing Stocks To Watch Today - October 16th - Daily Political

How Investors Are Reacting To Summit Therapeutics Stock Phase III Cancer Trial Collaboration

SMMT: Funding Risk Has Eased, HARMONi 3 Still Holds The Upside

Astrazeneca (NYSE:AZN) Stock Price Up 3.5% After Analyst Upgrade - Daily Political

AstraZeneca Partners with Insitro for $40M AI-Driven Drug Discovery, ETPharma

Training the next generation of hepatologists for the cardiovascular-kidney-metabolic era

Closing the gap: disparities in access to and implementation of guideline-directed medical therapy for CKM syndrome

AstraZeneca, Insitro strike AI drug discovery deal | Fox Business Video

1,227,801 Astrazeneca Plc $AZN Shares Sold by Ninety One UK Ltd

AstraZeneca strikes $40 million AI drug discovery deal with Insitro

Insitro, AstraZeneca Partner To Develop AI-Discovered Therapies For MASH And Herat Disease

AstraZeneca signs AI drug discovery deal with insitro worth up to $1.86 billion